Assessing Safety of Fibroblast Cell Therapy in Multiple Sclerosis: Hamid Khoja, PhD

Video

The chief scientific officer of FibroBiologics discussed the benefits of fibroblast cell technology in MS.

“What we’ve seen in our limited clinical trial is that these tolerogenic fibroblasts, or CybroCell, we don’t see any side effects, or we haven’t seen any side effects.”

This content originally appeared on our sister site, NeurologyLive.

Fibroblast cell technology seems to be safe for use in patients with multiple sclerosis (MS) and may offer a unique treatment approach. Hamid Khoja, PhD, chief scientific officer, FibroBiologics, discussed the technology, dubbed CYMS101, and the limited clinical trial that evaluated its safety.

Kohja discussed how patients treated with a 1-time infusion of CYMS101 did not experience any adverse events (AEs), unlike those treated with humanized monoclonal antibodies, although he did note the small scale of the study,

Patients enrolled in the safety study were monitored post-infusion for 4 hours and then at 4-week intervals for complete blood count and blood chemistry, where investigators again did not notice a difference. While experts opted for a single dose in the initial study, in the phase 1/2 clinical trial, multiple doses will be assessed, and investigators will look at multiple concentrations of cells to determine efficacy and safety. According to Khoja, FibroBiologics is aiming for a staggered approach to the clinical trial and anticipates filing an investigational new drug application in the third quarter of 2022.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
© 2025 MJH Life Sciences

All rights reserved.